Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-2-8
pubmed:abstractText
Brain derived neurotrophic factor (BDNF) expression is significantly reduced in the Parkinson's disease substantia nigra. This neurotrophin has potent affects on dopaminergic neuron survival protecting them from the neurotoxins MPTP and 6-hydroxydopamine (6-OHDA) commonly used to create animal models of Parkinson's disease and also promoting dopaminergic axonal sprouting. In this study, we demonstrate that an antisense oligonucleotide infusion (200 nM for 28 days) to prevent BDNF production in the substantia nigra of rats mimics many features of the classical animal models of Parkinson's disease. 62% of antisense treated rats rotate (P < or = 0.05) in response to dopaminergic receptor stimulation by apomorphine. 40% of substantia nigra pars compacta tyrosine hydroxylase immunoreactive neurons are lost (P < or = 0.00001) and dopamine uptake site density measured by (3)H-mazindol autoradiography is reduced by 34% (P < or = 0.005). Loss of haematoxylin and eosin stained nigral neurons is significant (P < or = 0.0001) but less extensive (34%). These observations indicate that loss of BDNF expression leads both to down regulation of the dopaminergic phenotype and to dopaminergic neuronal death. Therefore, reduced BDNF mRNA expression in Parkinson's disease substantia nigra may contribute directly to the death of nigral dopaminergic neurons and the development of Parkinson's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0014-4886
pubmed:author
pubmed:issnType
Print
pubmed:volume
192
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
226-34
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15698637-Animals, pubmed-meshheading:15698637-Binding, Competitive, pubmed-meshheading:15698637-Brain-Derived Neurotrophic Factor, pubmed-meshheading:15698637-Cell Death, pubmed-meshheading:15698637-Cell Survival, pubmed-meshheading:15698637-Disease Models, Animal, pubmed-meshheading:15698637-Dopamine, pubmed-meshheading:15698637-Dopamine Uptake Inhibitors, pubmed-meshheading:15698637-Down-Regulation, pubmed-meshheading:15698637-Male, pubmed-meshheading:15698637-Mazindol, pubmed-meshheading:15698637-Nerve Degeneration, pubmed-meshheading:15698637-Neurons, pubmed-meshheading:15698637-Neuroprotective Agents, pubmed-meshheading:15698637-Oligonucleotides, Antisense, pubmed-meshheading:15698637-Parkinsonian Disorders, pubmed-meshheading:15698637-RNA, Messenger, pubmed-meshheading:15698637-Radioligand Assay, pubmed-meshheading:15698637-Rats, pubmed-meshheading:15698637-Rats, Sprague-Dawley, pubmed-meshheading:15698637-Receptors, Dopamine, pubmed-meshheading:15698637-Substantia Nigra, pubmed-meshheading:15698637-Tyrosine 3-Monooxygenase
pubmed:year
2005
pubmed:articleTitle
Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
pubmed:affiliation
Department of Medicine, University of Melbourne, Level 7, Lance Townsend Building, Austin Health, Studley Road, Heidelberg, Vic 3084 Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't